Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Other: 2023-2025

Historic Receivables - Other for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.7 million.

  • Tonix Pharmaceuticals Holding's Receivables - Other fell 21.87% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 21.87%. This contributed to the annual value of $953,000 for FY2024, which is 79.24% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Receivables - Other stood at $1.7 million, which was down 17.63% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Receivables - Other ranged from a high of $4.6 million in Q4 2023 and a low of $242,000 during Q1 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Receivables - Other value was $1.6 million (recorded in 2023), while the average stood at $1.7 million.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Receivables - Other plummeted by 79.24% in 2024, and later soared by 432.64% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Receivables - Other stood at $4.6 million in 2023, then crashed by 79.24% to $953,000 in 2024, then decreased by 21.87% to $1.7 million in 2025.
  • Its Receivables - Other was $1.7 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.3 million in Q1 2025.